ESMO Breast Cancer 2026 Highlights: SERENA-6 - Summary - MDSpire

ESMO Breast Cancer 2026 Highlights: SERENA-6

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the SERENA-6 trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

Share

Objective:

To discuss the results from the SERENA-6 trial presented at the 2026 ESMO Breast Cancer Congress.

Approach:
  • Discussion: Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH provide insights on the trial outcomes.
Interpretation:

Conclusion:

Original Source(s)

ESMO Breast Cancer 2026 Highlights: SERENA-6

  • June 26, 2026

Related Content

Trends, survival and regional control of sentinel lymph node biopsy versus axillary dissection in cN0 breast cancer: a multicenter cohort in China

Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study

Quercetagetin-rich flavonoids from marigold induce apoptosis inhibit metastasis of non-small cell lung cancer via the p53/p21 signaling pathway